EW Stock Recent News
EW LATEST HEADLINES
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"). A class action has already been filed.
NEW YORK, NY / ACCESSWIRE / October 17, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
EW Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / October 17, 2024 / Hagens Berman urges Edwards Lifesciences Corporation (NYSE:EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 6, 2024 - July 24, 2024 Lead Plaintiff Deadline: Dec. 13, 2024 Visit: www.hbsslaw.com/investor-fraud/ew Contact the Firm Now: EW@hbsslaw.com 844-916-0895 Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences' disclosures about its core product, the Transcatheter Aortic Valve Replacement ("TAVR") platform.
LOS ANGELES, CA / ACCESSWIRE / October 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or "the Company") (NYSE:EW) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before December 13, 2024.
RADNOR, Pa. , Oct. 17, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is December 13, 2024.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2024 after the market closes on Thursday, October 24, 2024, and will host a conference call at 5:30 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edw.
Edwards Lifesciences Corporation investors that lost money on their investment are encouraged to contact BFA Law before December 13, 2024 legal deadline.
NEW YORK , Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now.